Bausch Health Companies Management
Management criteria checks 2/4
Bausch Health Companies' CEO is Tom Appio, appointed in May 2022, has a tenure of 1.92 years. total yearly compensation is $15.88M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $9.25M. The average tenure of the management team and the board of directors is 2.1 years and 7.8 years respectively.
Key information
Tom Appio
Chief executive officer
US$15.9m
Total compensation
| CEO salary percentage | 7.4% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.1yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation
Feb 24Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
Nov 30Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?
Nov 01
Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics
Sep 24Is Bausch Health Companies (NYSE:BHC) A Risky Investment?
Jul 24Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Jul 06What To Do After Bausch Health Stock Plunged By Nearly 9% Again
Jun 07Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt
Apr 18Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out
Dec 30Bausch Health acne lotion Arazlo available in Canada under public drug plans
Dec 22Bausch Health: Things To Consider Before Investing
Dec 11Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues
Nov 10Bausch Health Companies Q3 2022 Earnings Preview
Nov 02Bausch Health: Long-Term Need To Place Stops For Protection
Sep 28Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff
Sep 21Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic
Sep 08Bausch Health begin offers to exchange debt up to $4B
Aug 31Bausch Health Stock Down 11%: Now What?
Aug 09Bausch Health: How To Price The Calamities
Jul 31Bausch Health: Uncertain, Far From Healthy, But Potentially Lucrative
Jul 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$16m | US$1m | -US$592m |
| Sep 30 2023 | n/a | n/a | -US$963m |
| Jun 30 2023 | n/a | n/a | -US$186m |
| Mar 31 2023 | n/a | n/a | -US$357m |
| Dec 31 2022 | US$13m | US$1m | -US$225m |
| Sep 30 2022 | n/a | n/a | US$254m |
| Jun 30 2022 | n/a | n/a | US$43m |
| Mar 31 2022 | n/a | n/a | -US$407m |
| Dec 31 2021 | US$10m | US$854k | -US$948m |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$1b |
| Mar 31 2021 | n/a | n/a | -US$1b |
| Dec 31 2020 | US$4m | US$775k | -US$560m |
| Sep 30 2020 | n/a | n/a | -US$2b |
| Jun 30 2020 | n/a | n/a | -US$2b |
| Mar 31 2020 | n/a | n/a | -US$2b |
| Dec 31 2019 | US$4m | US$769k | -US$2b |
| Sep 30 2019 | n/a | n/a | -US$616m |
| Jun 30 2019 | n/a | n/a | -US$917m |
| Mar 31 2019 | n/a | n/a | -US$2b |
| Dec 31 2018 | US$4m | US$730k | -US$4b |
| Sep 30 2018 | n/a | n/a | -US$3b |
| Jun 30 2018 | n/a | n/a | -US$2b |
| Mar 31 2018 | n/a | n/a | -US$805m |
| Dec 31 2017 | US$3m | US$650k | US$2b |
Compensation vs Market: Tom's total compensation ($USD15.88M) is above average for companies of similar size in the US market ($USD6.57M).
Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.
CEO
Tom Appio (61 yo)
1.9yrs
Tenure
US$15,878,578
Compensation
Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$15.88m | 0.30% $ 9.2m | |
| Senior VP | 1.8yrs | US$1.40m | 0.0065% $ 203.3k | |
| Executive VP & General Counsel | 1.9yrs | US$3.16m | 0.063% $ 2.0m | |
| Senior VP & COO | 2.3yrs | no data | 0.024% $ 761.6k | |
| Senior Vice President of Sales & Salix | 1.3yrs | no data | no data | |
| Senior VP & Chief HR Officer | 2.3yrs | no data | no data | |
| Chief Medical Officer and President of R&D | no data | no data | no data | |
| Executive VP of Market Access | 3.8yrs | no data | no data | |
| Senior VP & Chief Quality Officer | 2.3yrs | no data | no data | |
| Senior Vice President of Europe & Canada | 2.3yrs | no data | no data | |
| Senior Vice President of Ortho Dermatologics | no data | no data | no data | |
| Senior Vice President of Solta Medical | 1.3yrs | no data | no data |
2.1yrs
Average Tenure
50yo
Average Age
Experienced Management: BHC's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$15.88m | 0.30% $ 9.2m | |
| Lead Independent Director | 8.1yrs | US$763.35k | 0.044% $ 1.4m | |
| Independent Chairman | 1.8yrs | US$812.50k | 0.000060% $ 1.9k | |
| Independent Director | 15.7yrs | US$389.55k | 0.045% $ 1.4m | |
| Chairman of External Advisory Board | no data | US$2.00m | no data | |
| Member of the External Advisory Board | 15.1yrs | no data | no data | |
| Member of the External Advisory Board | 15.1yrs | no data | no data | |
| Member of the External Advisory Board | 15.1yrs | no data | no data | |
| Independent Director | 3.1yrs | US$691.72k | 0.00020% $ 6.3k | |
| Independent Director | 7.8yrs | US$704.55k | 0.061% $ 1.9m | |
| Independent Director | 7.8yrs | US$377.50k | 0.046% $ 1.4m | |
| Independent Director | 3.1yrs | US$381.31k | 0.043% $ 1.4m |
7.8yrs
Average Tenure
68yo
Average Age
Experienced Board: BHC's board of directors are considered experienced (7.8 years average tenure).